Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors
US-10005785-B2 · Jun 26, 2018 · US
Radiolabelled mGluR2/3 PET ligands
US11045562B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11045562-B2 |
| Application number | US-201616061674-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 16, 2016 |
| Priority date | Dec 18, 2015 |
| Publication date | Jun 29, 2021 |
| Grant date | Jun 29, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound having the Formula or a pharmaceutically acceptable salt or a solvate thereof. 2. The compound according to claim 1 , having the Formula 3. A compound having the Formula or a pharmaceutically acceptable salt or a solvate thereof. 4. A process for the synthesis of compound comprising (a) the steps of (a-1) reacting a compound of Formula (P-1) with methanesulfonic anhydride in the presence of a base and an inert solvent, and (a-2) reacting the compound obtained in step (a-1) with [ 18 F]F − in the presence of a base in an inert solvent) or (b) the step of reacting a compound of Formula (P-2) with [ 18 F]F − in the presence of a base in an inert solvent or (c) the step of reacting a compound of Formula (P-3) with [ 18 F]F − in the presence of a base in an inert solvent
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
condensed with carbocyclic rings or ring systems · CPC title
with hetero atoms directly attached to ring nitrogen atoms · CPC title
Heterocyclic compounds · CPC title
Antidepressants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11045562B2 cover?
- The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the …
- Who is the assignee on this patent?
- Janssen Pharmaceutica Nv
- What technology area does this patent fall under?
- Primary CPC classification A61K51/0459. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).